Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
219.4 USD +0.04% Intraday chart for Biogen Inc. -4.64% -15.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer MT
AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases MT
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions CI
Eli Lilly Alzheimer's Drug Delayed as FDA Plans Advisory Panel Meeting -- Update DJ
US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel RE
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected RE
Biogen Says New Data Show Spinal Muscular Atrophy Drug Reduces Biomarkers in Infants, Toddlers MT
Transcript : Biogen Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 11:10 AM
Wall Street: a flurry of records, including that of the Nasdaq 'broad CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'. CF
AB Science: share price falls, negative opinion in Canada CF
Biogen: positive opinion from the CHMP in Charcot disease CF
Biogen Says EU Regulator's Committee to Recommend Marketing Authorization for Qalsody to European Commission MT
Nvidia and the moon Our Logo
Biogen’s Motor Neuron Disease Treatment Wins EU Regulatory Panel's Recommendation MT
EU medicines regulator backs Biogen's ALS drug RE
EMA Says Qalsody (Tofersen) Indicated For Treatment Of Adults With ALS RE
Canaccord Genuity Adjusts Price Target on Biogen to $305 From $310, Keeps Buy Rating MT
UBS Cuts Biogen Price Target to $250 From $276, Maintains Neutral Rating MT
Biogen Receives Subpoenas From DOJ, SEC MT
Biogen's Leqembi Continues to Have Long-Term Opportunity, RBC Says MT
Oppenheimer Adjusts Biogen Price Target to $290 From $295, Maintains Outperform Rating MT
The market faces a choice Our Logo
Baird Adjusts Biogen Price Target to $316 From $333, Maintains Outperform Rating MT
Needham Adjusts Biogen Price Target to $300 From $305, Maintains Buy Rating MT
Chart Biogen Inc.
More charts
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (78.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (16.7%) ; - other (4.8%): primarily revenues from partnership agreements.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
219.4 USD
Average target price
299.6 USD
Spread / Average Target
+36.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Biogen Inc. - Nasdaq
  4. News Biogen Inc.
  5. Biogen : JPMorgan Adjusts Biogen PT to $435 From $269, Maintains Neutral Rating